Literature DB >> 12709021

A potent adjuvant effect of CD40 antibody attached to antigen.

Tom A Barr1, Adele L McCormick, Jennifer Carlring, Andrew W Heath.   

Abstract

There is great potential for novel vaccines based on recombinant proteins and synthetic peptides. Unfortunately these antigens often lack the immunogenicity of whole, killed pathogens used in traditional vaccines. Thus there is strong interest in the identification of immunological adjuvants with low reactogenicity, but high potency, to enhance immune responses and realize the potential of these new vaccine strategies. CD40 antibodies have been shown to have adjuvant effects when administered at very high doses. These large doses are impractical and induce a cascade of cytokine release giving rise to septic shock-like symptoms, as well as splenomegaly and polyclonal antibody production. We show here that a very small amount of CD40 antibody can exhibit potent adjuvant effects when attached to soluble antigen. The lack of detectable systemic effects indicates that this method may be a powerful and practical means of enhancing the efficacy of recombinant vaccines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12709021      PMCID: PMC1782935          DOI: 10.1046/j.1365-2567.2003.01634.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  23 in total

1.  Effective priming of cytotoxic T lymphocyte precursors by subcutaneous administration of peptide antigens in liposomes accompanied by anti-CD40 and anti-CTLA-4 antibodies.

Authors:  D Ito; K Ogasawara; K Matsushita; T Morohashi; K Namba; N Matsuki; N Kitaichi; Y Inuyama; M Hosokawa; E Nakayama; K Iwabuchi; K Onoé
Journal:  Immunobiology       Date:  2000-04       Impact factor: 3.144

2.  CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.

Authors:  R R French; H T Chan; A L Tutt; M J Glennie
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

3.  Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb.

Authors:  D Ito; K Ogasawara; K Iwabuchi; Y Inuyama; K Onoé
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

4.  Anti-CD40 antibody enhances responses to polysaccharide without mimicking T cell help.

Authors:  C García de Vinuesa; I C MacLennan; M Holman; G G Klaus
Journal:  Eur J Immunol       Date:  1999-10       Impact factor: 5.532

5.  CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.

Authors:  L Diehl; A T den Boer; S P Schoenberger; E I van der Voort; T N Schumacher; C J Melief; R Offringa; R E Toes
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

6.  Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40.

Authors:  E M Sotomayor; I Borrello; E Tubb; F M Rattis; H Bien; Z Lu; S Fein; S Schoenberger; H I Levitsky
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

7.  Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.

Authors:  L Corey; A G Langenberg; R Ashley; R E Sekulovich; A E Izu; J M Douglas; H H Handsfield; T Warren; L Marr; S Tyring; R DiCarlo; A A Adimora; P Leone; C L Dekker; R L Burke; W P Leong; S E Straus
Journal:  JAMA       Date:  1999-07-28       Impact factor: 56.272

8.  Enhancement of T cell-independent immune responses in vivo by CD40 antibodies.

Authors:  P Dullforce; D C Sutton; A W Heath
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

9.  The induction of a protective response in Leishmania major-infected BALB/c mice with anti-CD40 mAb.

Authors:  W G Ferlin; T von der Weid; F Cottrez; D A Ferrick; R L Coffman; M C Howard
Journal:  Eur J Immunol       Date:  1998-02       Impact factor: 5.532

10.  Enhanced in vivo immune responses to bacterial lipopolysaccharide by exogenous CD40 stimulation.

Authors:  T A Barr; A W Heath
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

View more
  18 in total

1.  Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Kristin Kee; Celsa A Spina; Xiao-Fang Yu; Richard S Kornbluth
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

2.  CD40-mediated enhancement of immune responses against three forms of influenza vaccine.

Authors:  Caterina Hatzifoti; Andrew W Heath
Journal:  Immunology       Date:  2007-04-30       Impact factor: 7.397

3.  Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Renders B Cells Hyperresponsive to Secondary Infections.

Authors:  Sang-Hoon Sin; Anthony B Eason; Rachele Bigi; Yongbaek Kim; SunAh Kang; Kelly Tan; Tischan A Seltzer; Raman Venkataramanan; Hyowon An; Dirk P Dittmer
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

4.  Synergistic antibody induction by antigen-CD40 ligand fusion protein as improved immunogen.

Authors:  Wei Li
Journal:  Immunology       Date:  2005-06       Impact factor: 7.397

5.  CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge.

Authors:  Suefen Kwa; Lilin Lai; Sailaja Gangadhara; Mariam Siddiqui; Vinod B Pillai; Celia Labranche; Tianwei Yu; Bernard Moss; David C Montefiori; Harriet L Robinson; Pamela A Kozlowski; Rama Rao Amara
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

6.  Multivalent porous silicon nanoparticles enhance the immune activation potency of agonistic CD40 antibody.

Authors:  Luo Gu; Laura E Ruff; Zhengtao Qin; Maripat Corr; Stephen M Hedrick; Michael J Sailor
Journal:  Adv Mater       Date:  2012-06-12       Impact factor: 30.849

7.  TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs.

Authors:  Liang Cheng; Qi Wang; Guangming Li; Riddhima Banga; Jianping Ma; Haisheng Yu; Fumihiko Yasui; Zheng Zhang; Giuseppe Pantaleo; Matthieu Perreau; Sandra Zurawski; Gerard Zurawski; Yves Levy; Lishan Su
Journal:  J Clin Invest       Date:  2018-08-27       Impact factor: 14.808

8.  Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells.

Authors:  Anne-Laure Flamar; Yaming Xue; Sandra M Zurawski; Monica Montes; Bryan King; Louis Sloan; SangKon Oh; Jacques Banchereau; Yves Levy; Gerard Zurawski
Journal:  AIDS       Date:  2013-08-24       Impact factor: 4.177

9.  CD40mAb adjuvant induces a rapid antibody response that may be beneficial in post-exposure prophylaxis.

Authors:  Vijay Ns Bhagawati-Prasad; Evy De Leenheer; Nadine P Keefe; Lorna A Ryan; Jennifer Carlring; Andrew W Heath
Journal:  J Immune Based Ther Vaccines       Date:  2010-02-04

10.  Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Camila Santucci; Brian Tran; Robert Langer; Gregory T Zugates; Daniel G Anderson; Richard S Kornbluth
Journal:  PLoS One       Date:  2009-10-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.